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Abstract
Background: Alveolar echinococcosis (AE) is a life-threatening disease caused by larvae of the fox-tapeworm Echinococcus
multilocularis. Crucial to AE pathology is continuous infiltrative growth of the parasite’s metacestode stage, which is driven
by a population of somatic stem cells, called germinative cells. Current anti-AE chemotherapy using benzimidazoles is
ineffective in eliminating the germinative cell population, thus leading to remission of parasite growth upon therapy
discontinuation.
Methodology/Principal findings: We herein describe the characterization of EmPlk1, encoded by the gene emplk1, which
displays significant homologies to members of the Plk1 sub-family of Polo-like kinases that regulate mitosis in eukaryotic
cells. We demonstrate germinative cell-specific expression of emplk1 by RT-PCR, transcriptomics, and in situ hybridization.
We also show that EmPlk1 can induce germinal vesicle breakdown when heterologously expressed in Xenopus oocytes,
indicating that it is an active kinase. This activity was significantly suppressed in presence of BI 2536, a Plk1 inhibitor that has
been tested in clinical trials against cancer. Addition of BI 2536 at concentrations as low as 20 nM significantly blocked the
formation of metacestode vesicles from cultivated Echinococcus germinative cells. Furthermore, low concentrations of BI
2536 eliminated the germinative cell population from mature metacestode vesicles in vitro, yielding parasite tissue that was
no longer capable of proliferation.
Conclusions/Significance: We conclude that BI 2536 effectively inactivates E. multilocularis germinative cells in parasite
larvae in vitro by direct inhibition of EmPlk1, thus inducing mitotic arrest and germinative cell killing. Since germinative cells
are decisive for parasite proliferation and metastasis formation within the host, BI 2536 and related compounds are very
promising compounds to complement benzimidazoles in AE chemotherapy.
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Introduction
The metacestode larval stage of the fox-tapeworm E. multi-
locularis is the causative agent of alveolar echinococcosis (AE), a
life-threatening zoonosis prevalent in the Northern Hemisphere
[1,2]. Infection of the mammalian intermediate host (rodents,
humans) is initiated by oral uptake of ‘infectious eggs’, which
contain the oncosphere larva. Upon hatching from the egg in the
host intestine, the oncosphere penetrates the intestinal epithelium
and gains access to the host organs. Typically within the liver, the
parasite then undergoes a developmental transition towards the
metacestode stage which is entirely driven by parasite stem cells
(germinative cells) that have been carried to the host by the
oncosphere [2–4]. As an asexual multiplication stage, the
metacestode tissue grows multivesicularly and infiltratively, like a
malignant tumor, into the surrounding host tissue, eventually
leading to organ failure [1–4]. In natural rodent infections, head
regions of the future adult worm (protoscoleces) are formed from
germinative cells of the cellular layer (germinal layer; GL) of the
metacestode, and are subsequently taken up when the definitive
host takes its prey [4]. In human infections, asexual parasite
growth occurs similar to the situation in rodents, but protoscoleces
are only formed in rare cases [1]. Human AE is very difficult to
treat and only in,20% of cases the parasite mass can be removed
by surgery [1,2,5]. In all other cases, chemotherapy is the only
option of treatment and is currently mainly carried out using
benzimidazoles, which target parasite b-tubulin [5]. However, b-
tubulins between parasite and host are highly similar [6,7], so that
only parasitostatic concentrations of these drugs can be applied to
prevent significant adverse side effects [1,5,8]. Hence, although the
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introduction of benzimidazole chemotherapy in the 1990s has
significantly improved patient’s prognosis, treatment has to be
applied for years to decades, and in many cases even life-long
[1,5,8]. Furthermore, a significant number of patients cannot
tolerate benzimidazole treatment at all [1,5]. Several attempts to
improve anti-AE chemotherapy by identifying novel anti-parasitic
drugs are currently undertaken [8,9] but, so far, no reliable
alternative to benzimidazole treatment is available. This under-
scores an urgent need for novel chemotherapeutic options against
AE.
A hallmark of both free-living and parasitic flatworms is the
employment of a population of totipotent stem cells (called
‘neoblasts’ in free-living species) that decisively contribute to the
enormous regenerative capacity and developmental plasticity of
this group of organisms [4,10]. In Echinococcus, earlier ultrastruc-
tural studies also strongly suggested the presence of undifferenti-
ated stem cells (‘germinative cells’) in parasite larvae and is has
been hypothesized that they might contribute to parasite growth
[11,12]. By establishing cultivation techniques for germinative
cells, we later demonstrated their proliferative potential and
showed that they can form mature metacestode vesicles in vitro
[13]. Very recently, we also demonstrated that germinative cells
are the only proliferative cells in parasite larvae, that they give rise
to all differentiated cells, and that there are important differences
between the stem cell populations of E. multilocularis to those of the
related schistosomes, and to neoblasts of free-living flatworms [14].
Since the germinative cells are absolutely decisive for asexual
multiplication of the E. multilocularis metacestode, they constitute
one of the most important cell types for the development of
chemotherapeutics to prevent parasite proliferation.
Polo-like kinases (PLKs) are serine/threonine kinases (STK) that
act as important regulators of cell-cycle progression in all
eukaryotic lineages [15–17]. They are particularly important in
the M-phase during which they regulate the assembly of the
spindle apparatus and the activation of cyclin-dependent protein
kinases (CDC) [15–17]. In humans, five PLKs are expressed of
which Plk1-3 are very similar in structure. They comprise a
conserved N-terminal STK domain, necessary for phosphorylation
of downstream molecules, and two C-terminal Polo-box domains
(PBD), which govern protein-protein-interaction and subcellular
localization [15–17]. The so far best investigated PLK is
mammalian Plk1, which is mainly expressed in late G2 and M
phases and regulates both mitosis and meiosis [15,16]. Most
importantly, Plk1 activates the dual-specific phosphatase Cdc25C,
which dephosphorylates, and thus activates, the maturation
promoting factor (MPF), resulting in nuclear MPF translocation.
Since Plk1 is highly expressed in proliferating cells, including many
cancer cells, it has already been intensely validated as an anti-
cancer drug target, and several inhibitors that specifically inhibit
Plk1 activity are available [15,18].
In contrast to Plk1, Plk2 and Plk3 are encoded by early response
genes that are activated during serum stimulation of cells, and both
proteins are involved in checkpoint-mediated cell cycle arrest [15].
Plk4 is a divergent member of the PLK family and differs from
Plk1-3 in its domain composition. Plk4 shares little overall
homology with Plk1-3, and only contains one PBD [15]. Plk4
gene expression increases from late G1 to S phase, and the protein
is known to be involved in centriole duplication, and most
probably also plays a role in chromosome maturation and mitotic
progression [15]. Recently, a fifth PLK was identified in mammals,
Plk5, which is localized to the nucleolus and whose expression is
induced by stress conditions and DNA damage [15].
PLKs with structural and functional homologies to mammalian
Plk1 and Plk4 have already been described in invertebrate model
systems such as Drosophila melanogaster and Caenorhabditis elegans [17].
In free-living flatworms, functional studies on Polo-like kinases
have not yet been carried out, although their transcripts have been
specifically detected in neoblasts and reproductive organs of the
planarian Schmidtea mediterranea [19,20]. In parasitic flatworms,
PLKs have so far exclusively been investigated in the trematode
Schistosoma mansoni [17,21,22]. In a first study, Long et al. [21]
characterized SmPlk1, which displays considerable homologies to
mammalian Plk1, and demonstrated expression of the respective
gene in female vitelline cells and oocytes as well as in male
spermatocytes, indicating a role of SmPlk1 in schistosome mitosis
and/or meiosis. Interestingly, the PLK inhibitor BI 2536, which
was originally designed to inhibit human Plk1 [23], induced
dramatic alterations in schistosome gonads in vitro, which affected
oogenesis and spermatogenesis at 100 nM concentrations [21].
Very recently, the same authors also characterized a Plk4-like
PLK in S. mansoni, named SmSak, which was mostly expressed in
schistosome female ovary and vitellarium, and which interacted
with SmPlk1 [22]. In contrast to SmPlk1, however, the activity of
recombinantly expressed SmSak was not affected by Bi 2536,
indicating a high selectivity of this inhibitor for Plk1-like kinases
[17,22].
The successful identification of SmPlk1 in proliferative cells of S.
mansoni, and its inhibition by an available small molecule
compound, prompted us to investigate the role of PLKs in asexual
growth of E. multilocularis larvae. We herein describe the
characterization of a Plk1-like Echinococcus kinase, EmPlk1, and
demonstrate its expression in germinative cells of the Echinococcus
larval stages. We show that the activity of EmPlk1, when
heterologously expressed in the Xenopus oocyte system, can be
seriously affected by available PLK inhibitors. Furthermore, using
in vitro systems for the cultivation of parasite stem cells [13,24] and
metacestode larvae [25,26] we show that the compound BI 2536
significantly inhibits parasite development already at concentra-
tions as low as 20 nM. The potential of PLK inhibitors in anti AE
chemotherapy is discussed.
Materials and Methods
Ethics statement
In vivo propagation of parasite material was performed in
mongolian jirds (Meriones unguiculatus), which were raised and
Author Summary
The lethal disease AE is characterized by continuous and
infiltrative growth of the metacestode larva of the
tapeworm E. multilocularis within host organs. This
cancer-like progression is exclusively driven by a popula-
tion of parasite stem cells (germinative cells) that have to
be eliminated for an effective cure of the disease. Current
treatment options, using benzimidazoles, are parasitostatic
only, and thus obviously not effective in germinative cell
killing. We herein describe a novel, druggable parasite
enzyme, EmPlk1, that specifically regulates germinative
cell proliferation. We show that a compound, BI 2536,
originally designed to inhibit the human ortholog of
EmPlk1, can also inhibit the parasite protein at low doses.
Furthermore, low doses of BI 2536 eliminated germinative
cells from Echinococcus larvae in vitro and prevented
parasite growth and development. We propose that BI
2536 and related compounds are promising drugs to
complement current benzimidazole treatment for achiev-
ing parasite killing.
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housed at the local animal facility of the Institute of Hygiene and
Microbiology, University of Wu¨rzburg. This study was performed
in strict accordance with German (Deutsches Tierschutzgesetz,-
TierSchG, version from Dec-9-2010) and European (European
directive 2010/63/EU) regulations on the protection of animals.
The protocol was approved by the Ethics Committee of the
Government of Lower Franconia (Regierung von Unterfranken)
under permit number 55.2-2531.01-31/10.
Chemicals and inhibitors
PLK inhibitors BI 2536 [23] and BI 6727 (Volasertib) [27] were
purchased from Axon Medchem (Groningen, The Netherlands)
and Selleckchem.com (Mu¨nchen, Germany), respectively. Both
inhibitors were dissolved in dimethyl sulfoxide (DMSO) from
Sigma Aldrich (D8418-50ML) as 10 mM stock solutions and were
stored at 280uC until use (according to the manufacturer’s
instructions).
Parasite cultivation and inhibitor tests
All experiments were performed using the E. multilocularis
isolates H95 (cloning procedures; drug treatment) [28] and GH09
(whole mount in situ hybridization) [28]. Mongolian jirds (M.
unguiculatus) were used for in vivo propagation of the parasite by
intraperitoneal passages as previously described [26]. Co-cultiva-
tion of metacestode vesicles with host cells was carried out
essentially as previously described [26]. Axenic cultivation of
metacestode vesicles was performed as described by Spiliotis et al.
[25]. Echinococcus primary cells were isolated and cultivated under
axenic conditions as described by Spiliotis et al. [13]. Conditioned
medium (A4 medium) was prepared by seeding 16106 rat Reuber
hepatoma cells [26] together with 100 ml DMEM medium (Life
technologies) in a culture flask, followed by 1 week incubation.
Subsequently, the supernatant was removed and sterile filtrated
(A4 medium). Inhibitor tests on metacestode vesicles were
performed under axenic culture conditions (nitrogen atmosphere
[13]) in A4 medium as previously described by Hemer et al. [29]
and Gelmedin et al. [30], with up to ten vesicles per well of a 6-well
(5 ml vol. per well) culture plate. Primary cell cultures were set up
essentially as described by Spiliotis et al. [24] and the amount of
isolated cells was subsequently measured indirectly through
densitometry. 1 Unit of primary cells was defined as the amount
that yields an OD600 of 0.02 in Phosphate Buffered Saline (PBS).
50 Units isolated primary cells (,15.000 cells) were then seeded in
a 48-well plate with 1.3 ml A4-medium. Medium was changed
every second day and fresh inhibitor was added. Inhibitors were
used in final concentrations of 5, 10, 25, 50, and 100 nM. All
experiments were performed with at least three technical and
biological replicates. Linear regression analysis was carried out
using MicrosoftExcel-2007. Error bars in figures represent
standard deviation. Differences were considered significant for p
values below 0.05 (indicated by (*)), for p between 0.001 and 0.01
(**), and for p,0.001 (***). For p.0.5, differences were
considered non-significant.
Labeling of proliferating cells in metacestode vesicles by
EdU pulse staining
Proliferation of stem cells was investigated by staining of
newly synthesized DNA using the Click-iT EdU cell prolifer-
ation assay (Invitrogen, C10337). Metacestode vesicles from
hepatocyte co-culture [26] were washed once with 16PBS and
carefully transferred into a 15 ml tube containing 3 ml A4-
medium. A final concentration of 50 mM EdU (Component A)
was added and the metacestode vesicles were incubated for 5 h
at 37uC (with gentle agitation every 45 min). For fixation,
metacestode vesicles were transferred to a Petri-dish and
carefully opened with a syringe tip to remove hydatid fluid.
After intense washing with 16 PBS, fixative (4% paraformal-
dehyde (PFA) in 16 PBS) was added and samples were
incubated for 1 h at room temperature. The samples were
washed again (16 PBS) to remove the fixative, and then
transferred to a 1.5 ml tube. The EdU labeling procedure was
then carried out according to the manufacturer’s instructions
(Invitrogen, C10337), but with extended incubation times.
Metacestode vesicles were finally analyzed by fluorescence
microscopy.
For long-term treatment (21 days) with BI 2536, metacestode
vesicles were cultivated in A4-medium for 21 days with inhibitor
(medium and inhibitor change every second day), followed by
three days recovery without treatment. As a control, medium with
and identical amount of DMSO (without inhibitor) was used.
Randomly chosen metacestode vesicles (t = 4) were isolated and
EdU stained as outlined above.
Of each metacestode vesicle, three randomly chosen sections of
the GL were analyzed by microscopy and EdU positive cells were
counted. The number of EdU positive cells was calculated to cells
per mm2 of the GL.
For short-time inhibitor experiments, metacestode vesicles were
treated in vitro for 24, 48 and 72 hours with 50 nM or 100 nM BI
2536, followed by 24 h regeneration without inhibitor. EdU
staining and calculation of Edu positive cells per mm2 of GL were
subsequently performed as described above.
Identification and cloning of emplk1
The E. multilocularis genome sequence assembly [28] was used as
available in GeneDB under http://www.genedb.org/Homepage/
Emultilocularis. Published sequences of human Plk1 (GenBank
accession number: P53350) and SmPlk1 (AY747306) were
employed in extensive BLASTP searches on the genome sequence.
Amino acid sequence and domain predictions were carried out
using UniProt (http://www.uniprot.org/) and SMART (http://
smart.embl-heidelberg.de/) software. Based on the genomic
sequence information, primers were designed to amplify the full
EmPlk1 coding sequence. Total RNA was isolated from metaces-
tode vesicles with TRIzol reagent and reverse transcribed into
cDNA as previously described [30]. The cDNA then served as a
template for gene amplification by PCR using primers AKO-053
(59-GAC TTC TGC CCG GGT ATG GAT A-39) and AKO-054
(59-GGA AGA CGG CAA ACA TGT GAT-39). The PCR
product was subsequently cloned into pJET 1.2 (Thermo Scientific
CloneJET PCR Cloning Kit) and sequenced.
Expression of EmPlk1 in Xenopus oocytes
According to the previously described protocol for heterologous
expression of SmPlk1 in Xenopus oocytes [21], mutated versions of
EmPlk1 were produced which included a constitutively active form
of the kinase (T179D), a version that cannot be phosphorylated at
T179 (T179V), and kinase dead versions of wild-type EmPlk1 (wt
KD)
and T179D (T179D
KD). The kinase dead versions were generated
by replacing the highly conserved active loop motif D163FG for
D163SV. Kinase domain mutants were generated by mutagenesis
PCR using the following primer combinations: T179D (AKO-138,
59-GGT GAA ATG AAG AAG GAC TTA TGT GGG ACG
CCA AAC TAT ATT GCT CC-39 and AKO-139, 59-CCA CAT
AAG TCC TTC TTC ATT TCA CCT TCT TTA GTA ATT
CTA G-39), T179V (AKO-140, 59-GGT GAA ATG AAG AAG
GTA TTA TGT GGG ACG CCA AAC TAT ATT GCT CC-39
and AKO-141, 59-CCA CAT AAT ACC TTC TTC ATT TCA
Echinococcus Polo-Like Kinase 1
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CCT TCT TTA GTA ATT CTA G-39), and D163SV (AKO-146,
59-GAC ATG ATT GTA AAG ATC GGG GAT TCG GTG
TTG GCC TCT AGA ATT ACT AAA GAA GG-39 and AKO-
147, 59-GTA ATT CTA GAG GCC AAC ACC GAA TCC CCG
ATC TTT ACA ATC ATG TCA TCA TTT AAA AAC AGA
TTG GC-39). For mutagenesis, the emplk1 reading frame was
cloned into the pBAD TOPO/Thio expression vector (Life
Technologies). Mutations were then introduced, employing the
above listed primers, using the QuickChange Site-directed
mutagenesis kit (Agilent Technologies) according to the
manufacturer’s instructions. All plasmid constructs were finally
sequenced to verify wild-type sequences and the successful
introduction of the desired mutation. Wild-type and mutant
versions of the EmPlk1 reading frame were further cloned into
the pSecTag2/Hygro A vector (Life Technologies) that
contains a T7 promoter sequence. cRNA encoding EmPlk1
proteins was synthesized in vitro using the T7 mMessage
mMachine Kit (Ambion, USA) and injected in stage VI Xenopus
laevis oocytes according to [31].
Heterologous expression of EmPlk1 wild-type and mutant
forms in Xenopus oocytes, in vitro treatment of oocytes with the
inhibitors BI2536 and BI6727, and germinal vesicle break-
down assays were conducted essentially as previously described
by Long et al. [21] for SmPlk1. As a positive control for GVBD,
oocytes were stimulated with progesterone (PG), the natural
inducer. All experiments were carried out on samples
composed of 20 oocytes originated from three different Xenopus
females.
Semi-quantitative RT-PCR
Total RNA was isolated using TRIzol as previously described
[32] from 2, 5, and 11 day old primary cell cultures, from dormant
and pepsin/low pH activated protoscoleces [33], and from mature
metacestode vesicles. Isolated RNA was DNase treated (RQ1
RNase-free DNase, Promega) followed by phenol/chloroform
extraction. RNA concentration was quantified by spectrophotom-
etry and 750 ng of each stage were used for reverse transcription
(RT) as previously described [32]. Intron-flanking, gene specific
primers for emplk1 (AKO-57; 59-GAG CAT GTT CAG TGT
GAT GG-39 and AKO-60; 59-CGA TCT ATC ATA TCG TAG
GCG-39) were used to estimate the semi-quantitative expression
profile by PCR employing a protocol of 30 cycles of 30 sec at
94uC, 30 sec at 58uC, and 1 min at 72uC. The constitutively
expressed gene elp [34] served as a control.
Whole mount in situ hybridization (WISH) of metacestode
vesicles
Metacestode vesicles of isolate GHO9 with developing proto-
scoleces were used for in situ hybridization according to Koziol et
al. [14]. A 1.3 kb fragment of the emplk1 open reading frame was
amplified and subcloned into pDrive (Qiagen) using primers
AKO-55 (59-CTC TCA TGG AAC TGC ATA AGA G-39) and
AKO-60 (59-CGA TCT ATC ATA TCG ATG GCG-39).
Digoxygenin-labelled antisense and sense RNA probes were in
vitro transcribed using the T7 or SP6 promoter of the linearized
vector as previously described [14]. Detection was performed
using anti-digoxygenin antibodies coupled to alkaline phosphatase,
and NBT/BCIP as colorimetric substrates, as described [14].
Nucleotide sequence accession number
The complete emplk1 cDNA sequence reported in this paper was
submitted to the GenBank database and is available under
accession number HG931729.
Results
Cloning and characterization of the emplk1 cDNA
By BLASTP genome mining of the available E. multilocularis
genome sequence [28] (http://www.genedb.org/Homepage/
Emultilocularis) using the full length sequences of human Plk1
[35] and S. mansoni SmPlk1 [21] as queries, one single locus
encoding an Echinococcus Plk1 ortholog (EmuJ_000471700) was
identified on chromosome 3. Due to its homologies (see below), the
respective gene was designated emplk1 (E. multilocularis Polo-like
kinase 1) encoding the protein EmPlk1. The emplk1 gene spanned a
genomic region of 3.174 bp and, like the SmPlk1 encoding gene of
S. mansoni [21], comprised 7 exons, separated by 6 introns. All
introns displayed canonical GT-AG dinucleotide sequences at the
59 splice donor and the 39 splice acceptor sites. Informed by the
emplk1 genomic sequence, primers were designed to PCR-amplify
the entire emplk1 reading frame from metacestode cDNA
preparations. The cDNA fragment was cloned and fully
sequenced, which confirmed the exonic gene sequence as
determined by the E. multilocularis genome project. The full length
EmPlk1 reading frame comprised 1833 bp and coded for a protein
of 610 amino acids, EmPlk1, with a calculated molecular mass of
69.5 kDa. Analysis of the EmPlk1 protein sequence by SMART
[36] identified an N-terminal STK catalytical domain (between
Y22 and F274) and a C-terminal protein binding domain, which
included two Polo box domains (Figure 1). The EmPlk1 kinase
domain displayed sequence motifs characteristic of all 11 typical
sub-domains (I–XI) of protein kinases and included all residues
previously determined to be invariable for protein kinases [37] at
the respective positions (Figure 1). Particularly the sequence motifs
HRDLKxxN (sub-domain VI) and GTPNYIAPE (VIII) are strong
indicators for STK activity [37]. In human Plk1, residue T210 was
previously shown to be the major phosphorylation site of mitotic
PLKs [15] and a respective threonine residue was also conserved
in schistosome SmPlk1 (T182) [21]. In EmPlk1, this residue was
also conserved (T179; Figure 1). As in SmPlk1 [21] and human
Plk1 [35], the ATP binding site of EmPlk1 contained a
GxGGFAxC motif (Figure 1), which is a PLK-typical variation
of the canonical GxGxxGxV motif found in the majority of
protein kinases [37]. Overall, the EmPlk1 kinase domain displayed
significant homologies to the kinase domains of well investigated
PLKs such as S. mansoni SmPlk1 (68% identical residues), human
Plk1 (62%), Drosophila Polo (60%), and Xenopus Plx1 (60%).
Protein-protein interaction and cellular localization of PLKs
is regulated by the C-terminally located protein binding
domain [15]. As typical for Plk1-like PLKs, the EmPlk1
protein binding domain contains two Polo boxes (Y378-T441
and W475-Y545), which are separated from the kinase domain
by a non-conserved linker region. In human Plk1, three
residues (W414, H538, K540) have previously been shown to be
essential for the binding to phospho-S/T binding motifs, and
all three residues are also perfectly conserved in EmPlk1 (W371,
H499, K501; Figure 1).
Kothe et al. [38] previously identified several amino acid
residues that are important for binding of the PLK inhibitor BI
2536 to human Plk1. In particular, the absence of a bulky side
chain at position 132 (L132 in human Plk1) was an important
specificity determinant that ensured optimal binding of BI 2536 to
the Plk1 subfamily of PLKs [38]. In EmPlk1, all these residues,
including the leucine residue (L101), were conserved at the
respective positions (Figure 1).
Taken together, all above analyses clearly identified EmPlk1 as
a member of the Plk1 subfamily of PLKs, indicated that the
Echinococcus protein is most probably enzymatically active, and that
Echinococcus Polo-Like Kinase 1
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the PLK inhibitor BI 2536 should be able to bind to the parasite-
derived kinase.
Expression of emplk1 in E. multilocularis larval stages
To determine whether emplk1 is expressed in Echinococcus larval
stages relevant to the infection of the intermediate host, semi-
quantitative RT-PCR experiments were carried out. As relevant
parasite stages, we chose mature metacestode vesicles and
protoscoleces before and after activation by pepsin/low pH
(mimics transition into the definitive host), to cover late stages of
the infection. In our established primary cell cultivation system
[13,24], E.multilocularis germinative cells are capable of developing
into metacestode vesicles similar to the oncosphere metacestode
transition process [7]. Hence, in order to cover early stages of the
infection, we also included primary cell cultures at different time
points (2, 5, 11 days) of development. Total RNA was isolated and,
after cDNA preparation, emplk1 gene specific PCR was carried out
on serial dilutions. As shown in Figure 2, emplk1 transcripts could
be clearly identified in all larval stages tested, and particularly
prominent expression was observed in primary cell cultures, which
typically contain large proportions of parasite stem cells [13,14].
During the E. multilocularis genome project, preliminary deep
sequencing transcriptome data were generated for primary cell
cultures (2 and 11 days old) as well as for metacestode vesicles and
activated/dormant protoscoleces [28]. When we analyzed these
profiles we found particularly high expression in primary cell
cultures after 2 days of cultivation, which was reduced in primary
cells after 11 days, and basal in metacestode vesicles and
protoscoleces (Figure S1). This verified the RT-PCR data
mentioned above and, again, indicated possible stem cell specific
expression of emplk1 since young primary cell cultures contain
particularly high percentages of germinative cells, which steadily
decline during development (differentiation) into mature vesicles
[14].
emplk1 is specifically expressed in germinative cells
We recently investigated cellular proliferation profiles in E.
multilocularis development [14] and demonstrated that mitotically
active parasite stem cells are distributed throughout the germinal
layer, and are strongly accumulated in brood capsule and
protoscolex buds. In late stage protoscoleces, stem cells are
prominently located at the base of developing suckers, but are also
present in the posterior body [14]. To investigate a possible stem
cell specific expression of emplk1, we therefore carried out in situ
hybridization experiments using a recently established protocol
that is applicable to metacestode vesicles [14]. As depicted in
Figure 3, prominent emplk1 signals were obtained for all regions of
parasite larvae that typically contain large numbers of proliferating
stem cells, such as early brood capsules (Figure 3D), and
developing protoscoleces (Figure 3E,F). Furthermore, germinal
Figure 2. Expression of emplk1 in E. multilocularis larval stages. Total RNA was isolated from primary cell cultures (Pc) after 2, 5 and 11 days
(d2, d5, d11) of development towards the metacestode stage, from dormant (Ps_non) and pepsin/low pH-activated protoscoleces (Ps_act), as well as
from mature metacestode vesicles (Mc). The isolated RNA was reverse transcribed to cDNA and equal amounts of serial (10-fold) dilutions of cDNA
were subjected to gene-specific RT-PCR for emplk1 and the constitutively expressed gene elp (control) as indicated to the right. PCR products were
separated on a 1.5% agarose gel and stained with ethidium bromide. gDNA indicates positive control lanes where PCR has been performed on
genomic DNA. ‘RT-neg’ indicates the negative control where reverse transcriptase has been omitted. Marker sizes are indicated to the left.
doi:10.1371/journal.pntd.0002870.g002
Figure 1. Amino acid sequence and structural analysis of EmPlk1. The EmPlk1 amino acid sequence was aligned to Plk1-like enzymes of S.
mansoni (SmPlk1; GenBank accession number: AY747306), Homo sapiens (Plk1; P53350); D. melanogaster (Polo; P52304) and X. laevis (Plx1; P70032).
The predicted kinase domain is boxed, predicted Polo-boxes (Polo-box 1; Polo-box 2) are indicated above the alignment. Residues identical in at least
four of the sequences are shown in white on black background. The eleven sub-domains known to be highly conserved in kinases are indicated
above (I–XI). Highly conserved amino acid residues and sequence motifs are indicated above the alignment. The highly conserved threonine residue
which is critical for activation is marked by (T*) above the alignment. Residues important for phosphosubstrate binding of the C-terminal domain are
marked by (#) below the alignment. Residues involved in binding of BI 2536 to Plk1 are indicated by grey dots below the alignment.
doi:10.1371/journal.pntd.0002870.g001
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Figure 3. WISH detection of emplk1 transcripts. (A) General view of a metacestode hybridized with the emplk1 antisense probe. Note the
accumulation of emplk1 positive cells in the developing protoscoleces (arrows). (B) General view of a metacestode hybridized with the emplk1 sense
control probe. No signal is detected. (C–F) Details of emplk1 WISH detection in different developmental stages. (C) Detail of the metacestode
germinative layer, in which dispersed emplk1 positive cells can be distinguished (inset: higher magnification of a positive cell, combined with 49,6-
diamidino-2-phenylindole (DAPI) nuclear staining). (D) Accumulation of emplk1 positive cells in the early brood capsule bud (arrow). (E) Early
protoscolex development, with abundant emplk1 positive cells in the interior. (F) Late protoscolex development. emplk1 positive cells accumulate at
the base of the developing suckers (arrows). Bars represent 200 mm (A, B) and 50 mm (C–F).
doi:10.1371/journal.pntd.0002870.g003
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layer cells with a distribution highly reminiscent of germinative
stem cells stained positive for emplk1 (Figure 3C). Taken together,
these data strongly indicated that emplk1 is specifically expressed in
parasite stem cells.
EmPlk1 is enzymatically active
For functional studies on the schistosome PLK SmPlk1, the
heterologous Xenopus oocyte expression system has previously been
employed [21], and in the present study we used this system to
further characterize EmPlk1. To this end, we first generated a
mutant form of EmPlk1 in which T179 of the activation loop was
replaced by phospho-mimetic aspartate (T179D), thus yielding a
constitutively active form of the enzyme (similar to [21]). We also
produced a mutant in which T179 was replaced by valine (T179V),
which would prevent phosphorylation, and thus activation, at T179
in Xenopus oocytes. Finally, we produced ‘kinase dead’ versions by
replacing the D163FG motif of the active loop by D163SV in both
the wild-type and the T179D background (wt
KD; T179D
KD). In
Xenopus oocytes, it has already been demonstrated that the
injection of mRNA encoding activated forms of Plx1 (the Xenopus
Plk1-like kinase) or SmPlk1 can induce meiosis resumption, which
results in germinal-vesicle breakdown (GVBD) [21]. We therefore
injected mRNAs encoding the wild-type and mutant forms of
EmPlk1 into Xenopus oocytes and carried out GVBD assays.
As shown in Table 1, injection of (non-activated) wild-type
EmPlk1 alone was ineffective in inducing GVBD. However,
injection of the (activated) T179D mutant led to GVBD in 90% of
oocytes, which is comparable to activities previously determined
for SmPlk1 in this system [21]. The induction of GVBD by an
activated mutant of SmPlk1 in Xenopus oocytes has previously been
shown to involve increased phosphorylation of Xenopus Cdc25C
[21] and, although we did not specifically test this for EmPlk1, we
assume that the Echinococcus enzyme is also able to directly activate
the Xenopus downstream target. In the case of the kinase dead
version of activated EmPlk1 (T179D
KD), on the other hand, only a
basal rate (10%) of GVBD was observed (Table 1), indicating that
the kinase activity of EmPlk1 is responsible for meiosis resumption
in Xenopus. The T179V version of EmPlk1 was also completely
inactive in inducing Xenopus oocyte GVBD, indicating that
phosphorylation of EmPlk1 at T179 is essential for enzymatic
activity. It should be noted that BI 2536 was rather ineffective in
inhibiting GVBD in response to the positive control progesterone
(Table 1). This is in line with previous investigations showing that
progesterone-induced GVBD of Xenopus oocytes occurs via several
pathways, among which are the cAMP pathway (involving protein
kinase A) and the mitogen-activated protein kinase (MAPK)
pathway (including Mos, an oocyte-specific MAPKKK) [39].
Furthermore, meiosis entry of Xenopus oocytes in response to
progesterone also depends on a balance between Cyclin B
synthesis and the activity of Myt1, a member of the Wee1 family
of inhibitory kinases, in a Plx1- and MAPK-independent manner
[40]. Hence, although Plx1 is required for the activation of
Cdc25C in Xenopus oocytes [41], leading to accelerated meiosis
resumption, Plx1 inhibition can eventually not prevent GVBD.
The fact that even high concentrations of BI 2536 do not
significantly affect progesterone-induced GVBD in our experi-
ments thus indicates that this compound is not generally cytotoxic
to Xenopus oocytes and that the BI 2536 effects on EmPlk1 T179D-
induced GVBD solely result from the specific inhibition of the
parasite enzyme.
Taken together, these experiments verified that EmPlk1 is an
enzymatically active kinase that can stimulate meiosis resumption
in the Xenopus oocyte system similarly to SmPlk1.
EmPlk1 activity is affected by PLK-inhibitors
Having established that EmPlk1 can induce GVBD in Xenopus
oocytes, we then tested whether an available inhibitor, BI 2536,
originally designed against human Plk1 [23], is also able to affect
the parasite protein. As shown in Table 1, already at concentra-
tions as low as 5 nM, the capability of EmPlk1 to induce GVBD in
Xenopus oocytes started to diminish, and was completely abolished
at concentrations of 50 nM or higher. Similar results were
observed when we used BI 6727, another Plk1-specific inhibitor
with improved pharmacokinetic profile [27], although in this case
slightly higher concentrations were necessary to induce EmPlk1
inhibition (data not shown). Taken together, these experiments
indicated that EmPlk1 can be inhibited by BI 2536 and BI 6727 in
a concentration dependent manner.
BI 2536 affects metacestode development from stem
cells
Having established that the PLK inhibitor BI 2536 affects the
enzymatic activity of EmPlk1, we next investigated whether this
compound could also inhibit the formation of metacestode vesicles
from parasite stem cells. To this end, we set up Echinococcus
primary cell cultures and measured the formation of mature
metacestode vesicles in the presence of different concentrations of
BI 2536. As shown in Figure 4, metacestode formation was already
significantly reduced in the presence of 5 nM BI 2536, while
Table 1. Analysis of EmPlk1 activity in Xenopus oocytes.
BI2536 PG EmPlk1 (wt) T179D T179V EmPlk1 (wt
KD) T179D
KD
0 nM 90 0 90 0 0 10
1 nM - - 90 - - -
5 nM - - 80 - - 0
10 nM 90 - 20 - - -
20 nM - - 10 - - 0
50 nM - - 0 - - -
100 nM 80 - 0 - - 0
Wild-type (wt) and mutant forms (T179D, constitutively active; T179V, non-activatable; wt
KD, T179D
KD, kinase dead mutants) of EmPlk1 were expressed in Xenopus oocytes
(20 oocytes per set) and germinal vesicle breakdown (GVBD) assays were carried out in the presence of different concentrations of BI 2536 as indicated to the left.
Treatment by the natural inducer, progesterone (PG), served as a positive control. Displayed are the percentages of Xenopus oocytes that underwent GVBD in the
different experimental settings (mean of three independent experiments). ‘-’ indicates that this condition has not been tested.
doi:10.1371/journal.pntd.0002870.t001
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concentrations of 25 nM or higher almost completely prevented
parasite development. We also tested BI 6727 in the primary cell
culture system and, as BI 2536, this inhibitor prevented
metacestode vesicle formation in a concentration dependent
manner, although at slightly higher concentrations than BI 2536
(data not shown). Since the formation of metacestode vesicles in
the primary cell system crucially depends on proliferating stem
cells [14], and since we had already shown that EmPlk1 is
specifically expressed in this cell type (see above), we therefore
concluded that the inhibition of EmPlk1 by BI 2536 and BI 6727
either resulted in stem cell killing, or at least prevented stem cell
proliferation, in the primary cell system.
BI 2536 treatment affects the stem cell system of
metacestode vesicles
We then tested the effects of BI 2536 on mature metacestode
vesicles, which is the actual target stage of chemotherapy in AE
[1,5]. Interestingly, as shown in Figure S2, even incubation for 21
days in the presence of 100 nM BI 2536 did not lead to structural
disintegration or collapse of metacestode vesicles which, however,
had slightly reduced sizes and were no longer capable of growing.
This was similar to an approach we had recently undertaken
concerning metacestode treatment with the ribonucleotide reduc-
tase inhibitor hydroxyurea (HU), which is toxic to cells that
undergo proliferation [14]. Although HU treatment specifically
eliminated germinative cells in metacestode vesicles, these
remained structurally intact for several weeks, indicating that this
parasite stage is able to survive for long periods under conditions of
slow cellular turnover [14]. We therefore tested whether BI 2536
treatment of metacestode vesicles might specifically eliminate the
germinative cell population and carried out EdU incorporation
experiments. To this end, metacestode vesicles were incubated for
21 days in presence of different concentrations of BI 2536. After
recovery for 3 days without inhibitor, proliferating cells were
detected by EdU pulse labeling [14]. As shown in Figure 5, control
vesicles displayed a typical pattern of proliferating germinative
cells within the germinal layer. In samples treated with 10 nM BI
2536, however, the number of proliferating stem cells was reduced
by ,50%. A statistically significant reduction to ,10% of normal
numbers was observed after incubation with 25 nM BI 2536 and
in the presence of higher inhibitor concentrations (50, 100 nM),
cell proliferation in the germinal layer was completely abolished
(Figure 5). Like in our previous experiments using HU as an
inhibitor [14], no effects of BI 2536 treatment were observed on
differentiated cells. As expected from the absence of proliferating
cells, even after 3 weeks of further cultivation, these vesicles did not
resume growth or proliferation capacity (data not shown). Using
vesicles after 21 day treatment with 50 or 100 nM BI 2536 as a
source for parasite primary cell cultivation, we also never obtained
cultures that formed typical cell aggregates [13,14] or mature
metacestode vesicles (data not shown). Finally, we also carried out
short term treatment (24, 48, 72 h) of metacestode vesicles with
50 nM and 100 nM BI 2536 concentrations, followed by 1 day
recovery and 5 h EdU pulses. As shown in Figure 6, already after
24 h in the presence of 50 nM BI 2536, the number of
proliferating cells within the germinal layer was reduced to
,17% of the normal proliferating cell number, and it was further
diminished after incubation for 72 h or at higher concentrations
(100 nM; Figure 6).
Taken together, the experiments outlined above clearly
indicated that BI 2536 specifically targeted the germinative stem
cell population of metacestode vesicles and either led to stem cell
killing or long-term mitotic arrest.
Discussion
The pathology of AE is crucially linked to continuous asexual
growth of the E. multilocularis metacestode stage within the
intermediate host’s liver, accompanied by metastasis formation
in secondary organs [1,2,4,5]. Since somatic stem cells are
typically employed for cellular proliferation in flatworms (reviewed
in [10]), it has already very early been suggested that a population
of undifferentiated cells, which forms part of the Echinococcus GL, is
responsible for both tumor-like, infiltrative growth of parasite
larvae within host organs, and for metastases formation after
distribution through the lymphatic system of the host [11,12,42].
We previously developed methods to isolate and cultivate these
cells, and showed that they are capable of producing new
metacestode tissue when kept in culture in the presence of host-
derived feeder cells [13]. Very recently, we also showed that these
cells exhibit a typical stem cell character and that subpopulations
of these cells express several genes of the nanos and argonaute family
that are typical components of the germline multipotency program
of metazoan stem cells [14]. We also demonstrated that this cell
Figure 4. BI 2536 inhibits the formation of metacestode
vesicles from E. multilocularis primary cells. Primary cell cultures
were established from metacestode vesicles and incubated under ideal
growth conditions (A4 medium) in the presence of different concen-
trations of BI 2536 (5, 10, 25, 50, 100 nM) as indicated. After 14 days of
incubation, fully formed (mature) metacestode vesicles were counted
microscopically. ‘Control’ indicates cultures with A4 medium, ‘mock’
indicates cultures with DMSO (without inhibitor). All conditions were at
least assessed in three different biological replicates with at least three
technical replicates. *(p,0.05); **(p = 0.001–0.01) (Student’s t-test).
doi:10.1371/journal.pntd.0002870.g004
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type, called ‘germinative cells’, is the only cell type capable of
proliferation in E. multilocularis larvae and that it produces all
differentiated cell types present in the metacestode [14]. Since
germinative cells are capable of producing new metacestode tissue
even when removed from their normal tissue context in the
germinal layer [13], this cell type thus constitutes a crucial target
for the development of anti-Echinococcus drugs that aim to prevent
parasite proliferation and metastasis formation.
For decades, anti-AE chemotherapy has relied on benzimid-
azoles (mostly albendazole) [5], and although other compounds
with anti-parasitic activities are currently subject to intense
research [8,9,43], no reliable alternative to benzimidazole
treatment is currently in the pipeline. Unfortunately, little
information is available concerning direct effects of benzimid-
azoles on Echinococcus germinative cells. However, when we use
albendazole in cell killing assays on freshly isolated primary cell
cultures, which contain up to 80% germinative cells [14], little or
no effects are detected, even at high drug concentrations (Hemer,
Brehm, unpublished results). Indications for limited activity of
benzimidazoles on parasite stem cells were also obtained in earlier
studies by Ingold et al. [44] and Stettler et al. [45] who found that
albendazole derivatives only affected the germinative cells (called
‘undifferentiated cells’ in these publications) at late time points of in
vitro treatment of metacestode vesicles, and much less than other
compounds such as nitazoxanide. These in vitro studies were
recently verified in vivo by Ku¨ster et al. [46]. The fast recurrence of
parasite growth in patients after discontinuation of albendazole
chemotherapy [1,5,8], which has to rely on surviving germinative
cells [14], could therefore be due to limited activities of
benzimidazoles against this particular cell type. The molecular
basis for this limited efficacy could be stem cell-specific expression
of parasite b-tubulin isoforms that are resistant to inhibition by
benzimidazoles [7]. We have previously characterized three E.
multilocularis b-tubulin isoforms of which one, Tub-2, displayed
Figure 5. Long-term BI 2536 effects on E. multilocularis metacestode vesicles. Metacestode vesicles were treated for 21 days with different
concentrations (10, 25, 50 and 100 nM) of BI 2536, followed by three days of recovery without inhibitor. On day three of recovery, EdU labeling (5 h,
50 mM EdU) was carried out and labeled cells were microscopically counted. (A) Microscopic images of the GL of BI 2536 treated (10, 25, 50, 100 nM)
and non-treated E. multilocularis metacestode vesicles, stained with EdU. Bar represents 25 mm. Blue, nuclear staining, DAPI; red, EdU staining. (B)
EdU-positive cell counts per mm2 of GL. ‘Control’ indicates vesicles cultivated in A4 medium alone. ‘Mock’ indicates the DMSO control. ***(p,0.001)
(Student’s t-test). Please note that the specific examples shown in (A) display slightly different total cell numbers but that the overall cell numbers in
metacestode vesicles were not altered by drug treatment, as already outlined in [14] for HU treatment.
doi:10.1371/journal.pntd.0002870.g005
Figure 6. Short-term treatment of metacestode vesicles with BI
2536. Metacestode vesicles were treated for 24, 48 or 72 h (as
indicated) with 50 nM (light grey) or 100 nM (dark grey) of BI 2536,
followed by one day of recovery without inhibitor. EdU labeling (5 h,
50 mM EdU) was carried out and labeled cells were microscopically
counted. Shown are EdU-positive cell counts per mm2 of GL. ‘Control’
indicates vesicles cultivated in A4 medium alone. ‘Mock’ indicates the
DMSO control. ***(p,0.001) (Student’s t-test).
doi:10.1371/journal.pntd.0002870.g006
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amino acid sequence motifs that indicated limited interaction with
benzimidazoles [6] and in transcriptome analyses collected during
the E. multilocularis genome project [28], the Tub-2 encoding gene
(tub-2) displayed highest expression in parasite stages that are
enriched in germinative cells (Figure S3). Furthermore, in
preliminary transcriptome analyses on E. multilocularis larvae
(unpublished results), we already obtained evidence for stem cell-
specific expression of tub-2. Hence, apart from limited bioavail-
ability of benzimidazoles at the site of infection [8] and adverse
side effects due to high homologies between host- and parasite b-
tubulin [6], one of the drawbacks of benzimidazole chemotherapy
could be limited efficacy against germinative cells since these
express a potentially resistant b-tubulin isoform.
In the present work, we present information on a druggable
enzyme that fulfils a crucial role in Echinococcus germinative cell
proliferation. Our structural analyses clearly identified EmPlk1 as
a member of the Plk1-like subfamily of PLKs, with all protein
domains and catalytic residues that are typical for this enzyme
family at the corresponding positions. By heterologous expression
in Xenopus oocytes, we also demonstrated that EmPlk1 is an active
kinase that can induce meiosis resumption and GVBD. RT-PCR
analyses, transcriptome data, and in situ hybridization experiments
further indicated that EmPlk1 is specifically expressed in
Echinococcus germinative cells that are present in the germinal
layer of the metacestode and in developing protoscoleces. The
stem cell-specific expression of EmPlk1 is further supported by
preliminary deep sequencing transcriptome data of our group
which show that HU treated, and thus stem cell depleted,
metacestode vesicles [14] are dramatically reduced in emplk1
transcripts when compared to untreated metacestode vesicles
(unpublished data). Based on these data and on the conserved
functions of Plk1-like kinases in other metazoans [15–18], we
propose that EmPlk1 fulfils an important function in Echinococcus
germinative cells, particularly in dividing stem cells during G2/M
phase transition. An important upstream interaction partner of
human Plk1 is the kinase Aurora A, which phosphorylates, and
thus activates, Plk1 at T210 [15]. Since we have shown that
EmPlk1 also requires activation at a corresponding threonine
residue (T179) we propose that a similar activation mechanism also
exists in Echinococcus cells, and according to the genome sequence
[28], the parasite indeed encodes a gene encoding an Aurora A-
like kinase (EmuJ_001059700). Important downstream factors for
human Plk1 are the tyrosine phosphatase Cdc25c (also called M-
phase inducer phosphatase) which directs dephosphorylation of
cyclin B-bound CDK1 (cyclin-dependent kinase 1), thus triggering
entry into mitosis [15], the transcription factor forkhead box M1
(FoxM1), which regulates the expression of a cluster of G2/M
target genes, and the tumor suppressor p53 [15,16]. Orthologs to
these factors are also present in the Echinococcus genome, such as an
M-phase inducer phosphatase gene (EmuJ_001174300), a p53
ortholog (annotated as p63; EmuJ_000098700), and several genes
encoding forkhead transcription factors (e.g. EmuJ_000620400).
Notably, according to preliminary transcriptome data (unpub-
lished results), the genes encoding homologs to Aurora A, p53, and
several forkhead transcription factor genes are expressed in a
germinative cell-specific manner and could thus, together with
emplk1, form a regulatory network that controls the Echinococcus
stem cell cycle similar to the situation in humans [15,16].
In S. mansoni, Long et al. [22] recently characterized a Plk4-like
PLK, named SmSak, which interacts with SmPlk1 in Xenopus
oocytes, and which is co-expressed with SmPlk1 in the female
ovary and vitellarium. These authors showed that SmSak can be
activated following its interaction with SmPlk1, indicating a
potential role of SmSak in schistosome meiosis. SmSak was not,
however, inhibited by PLK-inhibitors directed against Plk1-like
family members. Together with their previous characterization of
SmPlk1 [21], these authors thus demonstrated that schistosomes
employ an invertebrate typical set of PLKs, consisting of one
member of the Plk1 and one member of the Plk4 sub-families. In
our BLASTP analyses, we also noted the presence of gene
encoding a second PLK in E. multilocularis (EmuJ_000104700).
However, although the kinase domain of the encoded protein
displayed similarity to PLK kinase domains, overall sequence
similarity of this protein was highest with Plk4 subfamily members
(including SmSak) and the protein obviously lacked conserved C-
terminal PBDs (data not shown). Of the 8 amino acid residues
known to be involved in the binding of Plk1 inhibitors (such as BI
2536) to human Plk1 [38], which were all conserved in EmPlk1,
only one was conserved in the kinase domain of this putative
EmSak. In the position corresponding to L101 of EmPlk1, which in
human Plk1 determines BI 2536 specificity [38], the kinase
domain of this protein contains a bulky residue (phenylalanine).
We therefore believe that the protein encoded by
EmuJ_000104700 fulfils similar activities as SmSak, particularly
in centriole duplication [22], and might even interact with
EmPlk1, but that none of the activities of BI 2536 discussed
below are due to inhibition of the kinase activity of this protein.
Due to its overexpression in many human tumors, Plk1 has been
extensively studied as a target for anti-cancer therapy and a
number of compounds that either act as ATP-competitive
inhibitors or interfere with Polo-box domain functions of Plk1
have already been identified [15,18]. One of the best studied
compounds in this regard is the ATP-competitive inhibitor BI
2536, which causes apoptosis and prometaphase arrest in a variety
of tumor cell lines [15,18,47,48]. In several phase I and phase II
clinical trials against lung or pancreatic cancer, BI 2536 was well
tolerated, albeit with varying success rates, depending on the
nature of the tumor [15,18,23,48–52]. In in vitro studies, BI 2536
usually displays activities against human tumor cell lines in an IC50
range between 5 and 175 nM [15,18,47,48] and, depending on
the intravenous doses given, tolerable plasma concentrations of BI
2536 in clinical trials on cancer patients vary between 20 and
200 nM [23,49–52]. This is well within the range of BI 2536
activities that we observed herein against EmPlk1 and E.
multilocularis larvae. As we have shown, concentrations as low as
20 nM BI 2536 almost completely inhibited the activity of EmPlk1
in Xenopus oocytes, and at higher concentrations (50, 100 nM),
EmPlk1 was no longer able to induce GVBD. Since all amino acid
residues previously determined to mediate binding of BI 2536 to
human Plk1 are also highly conserved in EmPlk1, it is reasonable
to assume that BI 2536-mediated inhibition of both enzymes
follows a similar ATP-competitive mechanism. We further
demonstrated that BI 2536 concentrations of 25 nM and higher
were very effective in preventing metacestode vesicle formation
from parasite germinative cells, and in depleting metacestode
vesicles of germinative cells. The specific elimination of germina-
tive cells in metacestode vesicles, which otherwise remained intact
for several weeks, is yet another indicator for stem cell specific
expression of EmPlk1, and we propose that the BI 2536 effects we
observed in the primary cell system are also due to EmPlk1
inhibition in the stem cell population. It is not yet clear whether BI
2536 treatment of parasite larvae induces germinative cell killing
or just (transient) mitotic arrest. However, even weeks after
treating metacestode vesicles with 50 or 100 nM BI 2536, we
never observed growth resumption or a re-population of the GL
with germinative cells. Furthermore, it was not possible to set up
proliferating parasite primary cell cultures from vesicles that had
been treated with 50 or 100 nM BI 2536. Together with
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observations that BI 2536 can induce apoptosis and severe
phenotypes in human cancer cells [15,18], we therefore hypoth-
esize that BI 2536 treatment of E. multilocularis indeed led to
germinative cell killing, or at least to permanent mitotic arrest.
Taken together, we herein present a promising target for the
development of anti-echinococcosis drugs that specifically affect
the germinative (stem) cell system of the parasite and, thus, would
ideally complement anti-parasitic activities of benzimidazoles. On
the one hand, BI 2536 itself could already be administered to
infected mice, combined with benzimidazoles, to study possible
additive effects. Respective experiments are currently planned in
our laboratory. Furthermore, BI 2536 could serve as a lead
compound for the identification of drugs that are more specific to
the parasite Plk1 when compared to human Plk1. Although the
kinase domains of both enzymes are homologous (62% identical
residues), they are clearly more divergent than are host and
parasite b-tubulins (.90% [6]), and should contain structural
differences that can be exploited for parasite-specific drug design.
This possibility is supported by the fact that the second generation
Plk1 inhibitor BI 6727, which has similar affinities and a similar
binding mode to human Plk1 as BI 2536 [27], was less effective in
preventing metacestode formation and in inhibiting EmPlk1 in the
Xenopus system than BI 2536 and also shows 4- and 11-fold less
selectivity against human Plk2 and Plk3, respectively, than BI 2536
[27]. Despite these somewhat lower activities of BI 6727 in
eliminating Echinococcus stem cells in vitro, it should not, however, be
dismissed as a potential anti-echinococcosis drug due to its clearly
improved pharmacokinetic profile and the fact that it can be given
orally [27]. Finally, our characterization of EmPlk1 as a factor that
governs the mitotic activity of E. multilocularis germinative cells will
form a solid basis for further investigations into the regulation of
the unique stem cell system of this parasite.
Supporting Information
Figure S1 Transcriptomic analysis of emplk1 expres-
sion in E. multilocularis larvae. Illumina transcriptome
sequencing has been carried out for some life cycle stages during
the E. multilocularis genome project [28]. Shown are fpkm
(fragments per kilobase of exon per million fragments mapped)
values for emplk1 for primary cells after 2 (PC2) and 11 days (PC11)
of development as well as metacestode vesicles (MC) and dormant
(PS2) and pepsin/low Ph-activated (PS+) protoscoleces. Note that
Illumina sequencing has been performed only once for each
sample.
(TIF)
Figure S2 Effects of BI 2536 on metacestode vesicle
integrity. Metacestode vesicles were treated for 21 days with
100 nM Bi 2536 and vesicle integrity was visually inspected. (A)
Number of structurally integer vesicles after treatment. (B) Culture
flasks showing vesicles after 21 day treatment (BI 2536, 100 nM)
and control vesicles. Note that the BI 2536 treated vesicles are
smaller and darker in appearance, but are still round and floating.
(TIF)
Figure S3 Transcriptomic analysis of b-tubulin gene
expression in E. multilocularis larvae. Illumina transcrip-
tome sequencing has been carried out for some life cycle stages
during the E. multilocularis genome project [28]. Shown are fpkm
(fragments per kilobase of exon per million fragments mapped)
values for the genes tub-1, tub-2, and tub-3 as indicated to the right.
Shown are values for primary cells after 2 (PC2) and 11 days
(PC11) of development as well as metacestode vesicles (MC) and
dormant (PS2) and pepsin/low Ph-activated (PS+) protoscoleces.
Note that Illumina sequencing has been performed only once for
each sample.
(TIF)
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